X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pomalidomide (484) 484
index medicus (261) 261
multiple myeloma (259) 259
lenalidomide (241) 241
humans (202) 202
hematology (180) 180
oncology (154) 154
thalidomide (150) 150
thalidomide - analogs & derivatives (146) 146
bortezomib (118) 118
multiple myeloma - drug therapy (109) 109
dexamethasone (98) 98
therapy (83) 83
carfilzomib (82) 82
low-dose dexamethasone (72) 72
female (71) 71
male (71) 71
thalidomide - therapeutic use (67) 67
animals (63) 63
survival (62) 62
aged (58) 58
thalidomide - administration & dosage (58) 58
pharmacology & pharmacy (57) 57
middle aged (53) 53
daratumumab (51) 51
antineoplastic combined chemotherapy protocols - therapeutic use (49) 49
thalidomide - pharmacology (47) 47
immunomodulatory drugs (46) 46
multiple myeloma - pathology (46) 46
drug therapy (45) 45
immunomodulation (44) 44
open-label (44) 44
adult (43) 43
multiple-myeloma (43) 43
patients (43) 43
cancer (42) 42
stem-cell transplantation (42) 42
treatment outcome (42) 42
care and treatment (40) 40
combination (40) 40
cereblon (39) 39
immunologic factors - therapeutic use (38) 38
dexamethasone - administration & dosage (36) 36
lenalidomide plus dexamethasone (36) 36
research (36) 36
analysis (34) 34
cells (34) 34
refractory multiple-myeloma (34) 34
aged, 80 and over (33) 33
thalidomide - adverse effects (33) 33
antineoplastic agents - therapeutic use (31) 31
article (31) 31
elotuzumab (29) 29
immunotherapy (29) 29
immunology (28) 28
degradation (27) 27
t-cells (27) 27
transplantation (27) 27
imids (26) 26
ixazomib (26) 26
mice (26) 26
prognosis (26) 26
medicine & public health (25) 25
recurrence (25) 25
thalidomide analogs (25) 25
chemotherapy (24) 24
clinical trials (24) 24
myeloma (24) 24
efficacy (23) 23
identification (23) 23
target (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
cell line, tumor (22) 22
immunologic factors - pharmacology (22) 22
plus dexamethasone (22) 22
proteins (22) 22
survival analysis (22) 22
abridged index medicus (21) 21
anemia (21) 21
angiogenesis (21) 21
hematology, oncology and palliative medicine (21) 21
multiple myeloma - mortality (21) 21
antineoplastic agents - pharmacology (20) 20
clinical trials as topic (20) 20
endogenous compound (20) 20
health aspects (20) 20
monoclonal antibodies (20) 20
proteasome inhibitors (20) 20
relapse (20) 20
tnf-alpha (20) 20
cyclophosphamide (19) 19
dosage and administration (19) 19
medicine, research & experimental (19) 19
angiogenesis inhibitors - therapeutic use (18) 18
biochemistry & molecular biology (18) 18
drug dosages (18) 18
ikaros (18) 18
imid (18) 18
in-vivo (18) 18
leukemia (18) 18
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (459) 459
Polish (11) 11
French (8) 8
Russian (7) 7
German (6) 6
Japanese (2) 2
Persian (2) 2
Chinese (1) 1
Czech (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2018, Volume 36, Issue 15, pp. TPS11586 - TPS11586
Conference Proceeding
BLOOD, ISSN 0006-4971, 11/2018, Volume 132
Conference Proceeding
HAEMATOLOGICA, ISSN 0390-6078, 10/2018, Volume 103, pp. S116 - S116
Conference Proceeding
NATURE, ISSN 0028-0836, 08/2014, Volume 512, Issue 7512, pp. 49 - 49
In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects. Despite the... 
MULTIPLE-MYELOMA | CELLS | PROTEIN | MENTAL-RETARDATION | RECOGNITION | MULTIDISCIPLINARY SCIENCES | LENALIDOMIDE | CEREBLON | POMALIDOMIDE | CANCER | CONGENITAL ABNORMALITIES
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2014, Volume 164, Issue 6, pp. 811 - 821
Cereblon ( CRBN ), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E 3 ubiquitin ligase complex, CRL 4 CRBN .... 
karos | iolos | ereblon | lenalidomide | pomalidomide | Pomalidomide | Cereblon | Ikaros | Lenalidomide | Aiolos | Ubiquitin | Genetic transcription | T cells | Ligases | Analysis | Haematological Malignancy
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 84, pp. 35476 - 35477
Journal Article
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, ISSN 2210-7703, 02/2018, Volume 40, Issue 1, pp. 260 - 260
Conference Proceeding
HAEMATOLOGICA, ISSN 0390-6078, 10/2017, Volume 102, pp. 139 - 140
Conference Proceeding
مجله علمی دانشگاه علوم پزشکی کردستان, ISSN 1560-652X, 03/2019, Volume 23, Issue 6, pp. 11 - 24
Background and Aim: Allergic asthma is an inflammatory disease of the respiratory system which causes an increase in inflammatory factors such as... 
Pomalidomide | prooxidant-antioxidant | Inflammation | Asthma
Journal Article
Onkogematologiâ, ISSN 1818-8346, 04/2019, Volume 14, Issue 1, pp. 8 - 13
Currently, there has been a marked increase in the number of opportunities for relapsed and refractory multiple myeloma treatment due to emergence of new... 
multiple myeloma | double refractory | pomalidomide
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 2015, Volume 16, Issue 8, pp. 3163 - 3166
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 8, pp. 957 - 958
Journal Article
مجله علمی دانشگاه علوم پزشکی کردستان, ISSN 2345-4040, 02/2019, Volume 23, Issue 6, pp. 11 - 24
Background and Aim: Allergic asthma is an inflammatory disease of the respiratory system which causes an increase in inflammatory factors such as... 
Pomalidomide | prooxidant-antioxidant | Inflammation | Asthma
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2018, Volume 18, pp. S256 - S256
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 10/2018, Volume 103, pp. S115 - S116
Conference Proceeding
Therapeutics and Clinical Risk Management, ISSN 1176-6336, 04/2015, Volume 11, pp. 549 - 556
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2016, Volume 34, Issue 15, pp. TPS8066 - TPS8066
Conference Proceeding
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 1, pp. 90 - 98
Purpose: Avadomide is a novel, small-molecule therapeutic agent that modulates cereblon E3 ligase activity and exhibits potent antitumor and immunomodulatory... 
CELLS | PHASE-II TRIAL | THERAPY | RESPONSE CRITERIA | ONCOLOGY | IKAROS | LENALIDOMIDE | DEGRADATION | THALIDOMIDE | AIOLOS | POMALIDOMIDE
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.